Omeros Return on Tangible Equity 2010-2024 | OMER
Current and historical return on tangible equity values for Omeros (OMER) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Omeros Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-12-31 | $-0.16B | $-0.18B | 117.07% |
| 2024-09-30 | $-0.13B | $-0.15B | 142.93% |
| 2024-06-30 | $-0.14B | $-0.13B | 238.30% |
| 2024-03-31 | $-0.12B | $-0.07B | 543.82% |
| 2023-12-31 | $-0.12B | $-0.03B | -1275.68% |
| 2023-09-30 | $0.02B | $-0.01B | 54.05% |
| 2023-06-30 | $0.04B | $0.02B | 141.38% |
| 2023-03-31 | $0.05B | $0.06B | 303.23% |
| 2022-12-31 | $0.05B | $0.09B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.05B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.03B | -280.14% |
| 2022-03-31 | $0.20B | $-0.01B | -160.00% |
| 2021-12-31 | $0.19B | $0.02B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.26B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.25B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.22B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.12B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.09B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.16B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.11B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.14B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.13B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.229B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $223.673B | 26.90 |
| Boston Scientific (BSX) | United States | $152.309B | 38.13 |
| Stryker (SYK) | United States | $147.454B | 30.83 |
| EssilorLuxottica (ESLOY) | France | $127.910B | 0.00 |
| Medtronic (MDT) | Ireland | $108.054B | 15.78 |
| Lonza Group Ag (LZAGY) | Switzerland | $48.940B | 0.00 |
| Haleon (HLN) | United Kingdom | $46.883B | 26.67 |
| ResMed (RMD) | United States | $36.216B | 27.20 |
| GE HealthCare Technologies (GEHC) | United States | $33.352B | 15.84 |
| Agilent Technologies (A) | United States | $31.795B | 21.00 |
| Terumo (TRUMY) | Japan | $28.308B | 36.77 |
| Insulet (PODD) | United States | $22.619B | 88.79 |
| Koninklijke Philips (PHG) | Netherlands | $22.446B | 16.14 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.861B | 12.11 |
| Baxter (BAX) | United States | $15.559B | 11.62 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.250B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.032B | 0.00 |
| Demant (WILYY) | Denmark | $8.030B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.641B | 22.45 |
| Lantheus Holdings (LNTH) | United States | $5.453B | 13.75 |
| Prestige Consumer Healthcare (PBH) | United States | $4.220B | 18.85 |
| Perrigo (PRGO) | Ireland | $3.576B | 9.06 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.449B | 15.02 |
| ICU Medical (ICUI) | United States | $3.346B | 24.67 |
| Envista Holdings (NVST) | United States | $3.039B | 25.25 |
| QuidelOrtho (QDEL) | United States | $2.269B | 15.60 |
| GN Store Nord (GNNDY) | Denmark | $2.150B | 17.81 |
| LeMaitre Vascular (LMAT) | United States | $1.875B | 41.92 |
| AtriCure (ATRC) | United States | $1.597B | 0.00 |
| Neogen (NEOG) | United States | $1.385B | 17.72 |
| AdaptHealth (AHCO) | United States | $1.200B | 12.19 |
| Green Thumb Industries (GTBIF) | United States | $1.173B | 26.38 |
| Kestra Medical Technologies (KMTS) | United States | $1.150B | 0.00 |
| BioLife Solutions (BLFS) | United States | $1.047B | 0.00 |
| InMode (INMD) | Israel | $1.013B | 9.28 |
| Phibro Animal Health (PAHC) | United States | $0.946B | 12.10 |
| Evolus (EOLS) | United States | $0.644B | 0.00 |
| CeriBell (CBLL) | United States | $0.595B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.585B | 0.00 |
| Owens & Minor (OMI) | United States | $0.541B | 4.49 |
| Valneva SE (VALN) | France | $0.536B | 0.00 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.504B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.444B | 0.00 |
| Surmodics (SRDX) | United States | $0.399B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.350B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.341B | 0.00 |
| SNDL (SNDL) | Canada | $0.336B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.317B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.307B | 11.29 |
| Sanuwave Health (SNWV) | United States | $0.293B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.283B | 50.40 |
| Sanara MedTech (SMTI) | United States | $0.278B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.272B | 22.90 |
| Verano Holdings (VRNOF) | United States | $0.261B | 0.00 |
| Canopy Growth (CGC) | Canada | $0.259B | 0.00 |
| ZimVie (ZIMV) | United States | $0.243B | 11.04 |
| Cerus (CERS) | United States | $0.239B | 0.00 |
| Biote (BTMD) | United States | $0.216B | 6.06 |
| Brainsway (BWAY) | Israel | $0.194B | 51.35 |
| High Tide (HITI) | Canada | $0.190B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.186B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.178B | 14.38 |
| Quanterix (QTRX) | United States | $0.166B | 0.00 |
| Organigram Global (OGI) | Canada | $0.163B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.158B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.139B | 17.18 |
| Exagen (XGN) | United States | $0.124B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.118B | 0.00 |
| Agape ATP (ATPC) | $0.105B | 0.00 | |
| Jin Medical (ZJYL) | China | $0.100B | 0.00 |
| MacroGenics (MGNX) | United States | $0.098B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.090B | 0.00 |
| Fonar (FONR) | United States | $0.076B | 10.64 |
| Veru (VERU) | United States | $0.074B | 0.00 |
| InterCure (INCR) | Israel | $0.069B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.067B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| United Health Products (UEEC) | United States | $0.061B | 0.00 |
| Apyx Medical (APYX) | United States | $0.053B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.051B | 0.00 |
| ImmuCell (ICCC) | United States | $0.044B | 0.00 |
| Modular Medical (MODD) | United States | $0.039B | 0.00 |
| United-Guardian (UG) | United States | $0.037B | 12.84 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.033B | 0.00 |
| Nephros (NEPH) | United States | $0.022B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.022B | 0.00 |
| INLIF (INLF) | $0.018B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.016B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.014B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.009B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |